[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025",
    "summary": "Amgen (AMGN) recently declared a $2.38 dividend per share, continuing its practice of rewarding shareholders, which aligns with a 5.6% price increase over the last quarter. During this period, Amgen announced successful Phase 3 clinical trial results, potentially boosting investor confidence. Additionally, amidst broader market volatility influenced by weak job reports and tariff concerns, Amgen's strong clinical outcomes and dividend declaration might have cushioned its stock against broader...",
    "url": "https://finnhub.io/api/news?id=fcb94c3dd9908e90b011a0e6aca830733ac8f7a4353bb1a1b7a387e99637a832",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754154742,
      "headline": "Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025",
      "id": 136183373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) recently declared a $2.38 dividend per share, continuing its practice of rewarding shareholders, which aligns with a 5.6% price increase over the last quarter. During this period, Amgen announced successful Phase 3 clinical trial results, potentially boosting investor confidence. Additionally, amidst broader market volatility influenced by weak job reports and tariff concerns, Amgen's strong clinical outcomes and dividend declaration might have cushioned its stock against broader...",
      "url": "https://finnhub.io/api/news?id=fcb94c3dd9908e90b011a0e6aca830733ac8f7a4353bb1a1b7a387e99637a832"
    }
  }
]